BHCM
FULC icon

Brevan Howard Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Brevan Howard Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$303K Sell
39,444
-9,456
-19% -$87.7K ﹤0.01% 1611
2025
Q4 		$559K Buy
48,900
+33,597
+220% +$342K 0.01% 1048
2025
Q3 		$141K Buy
+15,303
New +$111K ﹤0.01% 1824
2024
Q2 		– Sell
-88,483
Closed -$835K – 1166
2024
Q1 		$835K Buy
+88,483
New +$790K 0.01% 315

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Brevan Howard Capital Management's FULC Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 19% in Q1 2026, selling an estimated $87.7K and leaving 39,444 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Brevan Howard Capital Management first reported a position in FULC in Q1 2024 and has held it in 4 quarters since. The position peaked at $835K in Q1 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Brevan Howard Capital Management held 39,444 shares of Fulcrum Therapeutics worth $303K as of Q1 2026.
  • Brevan Howard Capital Management sold 9,456 Fulcrum Therapeutics shares in Q1 2026, an estimated $87.7K.
  • Fulcrum Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1611 holding.
  • Brevan Howard Capital Management first reported a position in Fulcrum Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Fulcrum Therapeutics position peaked at $835K in Q1 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.